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Aim. The purpose of the present study was to analyze the predictive and prognostic role of soluble (pro)renin receptor (sPRR)
as a biomarker for clinicopathological outcome in patients with primary epithelial ovarian cancer (EOC). As part of the renin-
angiotensin system (RAS) whose activity is known to increase in ovarian cancer patients, the relation of sPRR and ovarian cancer
should be further investigated. Patients and Methods. In this study 197 patients with primary EOC in our institution from 2000
to 2011 were included. sPRR was determined by enzyme-linked immunosorbent assay (ELISA) in preoperative taken blood sera.
Associations with clinicopathological outcome were analyzed and serum levels of sPRR in patients have been compared to those
in healthy specimen. Kaplan-Meier and logistic/Cox regression assessed the impact of the markers on progression-free survival
(PFS) and overall survival (OS). Results. There have been no correlations proved of sPRR levels with neither clinicopathological
factors nor prognostic data. Also the distribution of sPRR in patients and controls was normal. Conclusion. sPRR seems to have
no predictive, prognostic, or diagnostic value in EOC. As several factors of the RAS which might indicate cancer events have been
shown, sPRR seems not to be affected.
1. Background
Epithelial ovarian cancer (EOC) is the leading cause of death
for gynaecological cancers. Its poor prognosis is contingent
on various factors: (a) nearly 70% of the concerned women
have advanced FIGO stages with extrapelvic metastasis at
diagnosis [1], (b) more than 20% are resistant to chemother-
apy, (c) furthermore EOC’s molecular complexity makes
targeted chemotherapy andpotent diagnosticmarker difficult
to establish, and (d) more than 60% of the patients will
relapse [2]. Currently standard of care is debulking surgery
followed by platinum-taxane chemotherapy. After surgery
the largest diameter of the residual tumour mass is recorded
and acts with FIGO stage at diagnosis as the strongest
prognostic factor [3]. Moreover ascites before surgery [4] and
the temporal context of debulking surgery and chemotherapy
[5] have a strong clinical prognostic value aswell.TheROVAR
(Risk Of Ovarian Cancer Relapse) score categorises EOC
patients into three risk groups by determining preoperative
CA-125, FIGO stage, histological grading, and presence of
residual disease at posttreatment [2] and accomplishes a
sensitivity and specificity for relapse of 94% and 61%.
With the determination of EOC’s tumorigenesis and its
certain histopathologies and molecular subclassifications the
development of specific therapies for the different types of
EOC becomes achievable. Predictive or prognostic associa-
tions with such subgroups might occur as well.
Therefore on the one hand powerful diagnostic markers
for earlier diagnosis and on the other hand predictive and
prognostic markers to dedicate suitable targeted therapies to
the patients are needed.They can be used to identify themost
benefitting therapy management for those women.Therefore
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random tumour markers and markers that have been found
upregulated in the environment of EOC are in the focus of
research. In this study we determined the soluble form of
(pro)renin receptor (PRR).
The (pro)renin receptor (PRR) has four main functions
in the human body. Initially the receptor was described by
Ludwig et al. in 1998 as a component of V-ATPase and called
ATP6M8-9 [6]. Later it was discovered by Nguyen et al.
in 2002 that linking renin or prorenin to this receptor (a)
starts the cascade of tissue renin-angiotensin system (RAS)
with the conversion of angiotensinogen into angiotensin I
and (b) also initiates intracellular mitogen-activated protein
kinase (MAPK) pathways [7]. In recent studies PRR has been
revealed to act as an adaptor protein between V-ATPase and
LRP6, which are parts of the Wnt receptor complex [8].
Such Wnt cascades are known to affect oncogenesis [9] and
cardiorenal end-organ damage [10].
As there are studies proving that the activity of the RAS
is increased in ovarian cancer patients, we decided to inves-
tigate also the cascade-starting receptor PRR. Such increased
activity is characterised by, for example, angiotensin II type
1 receptor (AGTR1), which has a prognostic role in EOC
[11], or angiotensin converting enzyme (ACE) which is
upregulated in cancer patients [12]. The presence of a soluble
form (sPRR) makes the receptor more likely to become
an easy quantifiable marker. It is proved that blocking the
AGTR1 with candesartan in vitro and in mice reduces peri-
toneal carcinomatosis, decreases ascitic VEGF concentration,
and prevents angiogenesis [13]. Therefore a possible similar
impact of sPRR should be investigated.
2. Materials and Methods
2.1. Patients. In this study 197 patients with primary EOC
were included.The serum samples have been obtained before
cytoreductive surgery between 2000 and 2011. They were
collected and the data of the patients was regularly updated
by the Tumor Bank of Ovarian Cancer (http://www.toc-
network.de/). TOC is amulticentre project at theDepartment
of Gynaecology at Campus Virchow Clinics, Berlin, which
started in 2000 and is still running. The clinics have an
emphasis on multimodal therapy of ovarian cancer for more
than 15 years.The follow-up of all patients in this study ended
2013 and has amean of 44.8months (range 3–114) only ending
with the death of a patient.
The median age of the patients at date of diagnosis was
60 years ranging from 28 to 92 years. 181 patients (91.9%)
had already advanced tumour disease (FIGO III/IV) at
presentation.All patientswere treatedwith debulking surgery
and 170 patients (86.3%) got chemotherapy over 6.2 cycles
on average (ranged 1–16). Taxol and carboplatin were given
to 154 (78.2%) women, 11 (5.6%) were treated with other
platinum containing combinations, and 5 patients (2.5%)
received immunotherapy.
For comparison 132 specimens from healthy asymp-
tomatic women were collected at the University Medical
Center Go¨ttingen. All serum specimenswere processed using
the same protocol.Theirmedian agewas 57.5 years (range 42–
83).
The serum levels of sPRR have been assayed by CellTrend
GmbH (http://www.celltrend.de/) with ELISA.
2.2. ELISA. To determine sPRR CellTrend uses a direct
sandwich ELISA. The specific antibody is precoated onto a
microplate. The samples and standards are pipetted into the
wells and incubated for 120minutes. Following this, any sPRR
present is bound. After washing a biotin-labelled antibody is
added and incubated again for 60minutes.Thereafter another
wash follows and enzyme-linked streptavidin subjoins. A
substrate solution is pipetted to the wells after 60 mins
of incubation and washing. In 30 minutes of incubation a
colourful solution establishes. The absorption is measured at
450 nm with an ELISA reader and behaves proportionally to
the sPRR concentration.The sPRR levels are labelled in U per
millilitre.
2.3. Statistical Methods. For the statistical evaluations IBM
SPSS Statistics ver. 22 (SPSS Inc., Chicago, IL, USA) was used.
Spearman’s rho, Kruskal-Wallis test, and Mann-Whitney 𝑈
test were applied to determine the association between sPRR
levels and clinicopathological factors as well as between
patients and healthy controls. The 𝛼-level was assumed as
<0.05. Kaplan-Meier analysis provided quartile estimates.
The survival distributions have been compared with log-
rank (Mantel-Cox). Any clinically or histologically confirmed
cancer recurrence was defined as an event for the calculation
of progression-free survival (PFS). The overall survival (OS)
is defined as the interval between date of diagnosis and the
death of the patients.
The clinical and pathological factors were mass of ascites,
FIGO classification, age at diagnosis, residual tumour mass
after surgery, histological WHO grading, histology, response
to platinum-based therapy, and PFS and OS in patients with
primary EOC.
Ethical approval was obtained from the Ethical Commit-
tee, Charite´ Medical University, Berlin (number 207/2003),
University Medical Center Go¨ttingen (no. EK 22/2/04).
Written informed consentwas provided by the patients before
enrolment and serum sample collection.
3. Results
In this study we investigated serum samples of 197 patients
with primary EOC. The median age of the group was 60
years, ranging from 28 to 92. 91.9% of the patients had
advanced FIGO stage III or IV. The distribution of histology,
histological grading, volume of ascites before surgery, and
existence of peritoneal carcinomatosis is shown in Table 1.
All included patients had cytoreductive surgery after
taking the serum samples, whereas 2 patients (1.02%) got
neoadjuvant chemotherapy and 35 patients (17.8%) came for
completing surgery next to 2 patients (1.02%) with interval
surgery. There was no residual tumour mass after surgery in
103 women (52.3%); on the other hand in 22 (11.2%) cases
the biggest diameter of nonresectable tumour was more than
2 cm. Eight patients (4.1%) died from post-op complications
and 128 patients (65%) died by now in total.
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Table 1: Patient’s clinical and pathologic characteristics.
Age in years at diagnosis Median 60 (range 28–92)
Follow-up period in months Mean 44.5 (range 1–114)
Parameters 𝑁 %
197 patients
Histology
Serous 183 92.9
Endometrioid 1 0.5
Clear cell tumour 1 0.5
Mixed 4 2.0
Others 8 4.1
FIGO
I 5 2.5
II 11 5.6
III 135 68.5
IV 46 23.4
Histological grading
I 8 4.1
II 49 24.9
III 140 71.0
Volume of ascites
No ascites 47 23.9
<500mL 77 39.1
>500mL 73 37.0
Peritoneal carcinomatosis
Present 174 88.3
Residual tumour mass
No residual tumour mass 103 52.3
<0,5 cm 34 17.3
<1 cm 30 15.2
1-2 cm 6 3.0
>2 cm 22 11.2
No tumour 2 1.0
Response to platinum-based
chemotherapy
Platinum sensitive 116 58.9
Platinum resistant 55 27.9
No platinum chemo 26 13.2
171 patients were treated with chemotherapy. 116 (58.9%)
of the patients reacted sensitively to platinum which was
defined according to Gyneacologic Cancer InterGroup
(GCIG) criteria as no relapse within six months after
platinum-based chemotherapy.
3.1. sPRR Expression in Ovarian Cancer Patients versus
Healthy Controls. The serum levels of sPRR in EOC patients
and control group are shown in Table 2. The values did not
correlate significantly with the presence of cancer. Figure 1
illustrates this relation.
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Figure 1: sPRR levels in patients and controls.
Table 2: Mean and median of serum levels and 𝑝 value of sPRR.
Mean Median Mean Median 𝑝 value
(Mann-Whitney 𝑈
test)
In patients
(𝑁 = 197)
In controls
(𝑁 = 200)
sPRR in
U/mL
24.57
(range
0.0–
318)
13.2
29.122
(range
5.7–
282.8)
11.1 0.119
Table 3: 𝑝 value and Spearman’s rank for the clinicopathological
parameters and sPRR.
Parameters & sPRR 𝑝 value
Ascites 0.298
FIGO classification 0.066
Age at diagnosis 0.069
Residual tumour mass after surgery 0.224
Grading 0.531
Histology 0.316
Platinum response 0.194
3.2. Correlation of sPRR Expression with Clinical, Prognostic,
and Histological Factors in Ovarian Cancer Patients. The 𝑝
values of the correlations with the clinicopathological factors
are shown in Table 3. There are no significant correlations
with the sPRR levels.
3.3. Impact of sPRR Expression on Survival. The median PFS
of the whole group was 14 months ranging from 0 to 114
months. The time of PFS has been defined as period between
surgery and occurrence of relapse. Furthermore the whole
group had a median OS of 40 months ranging from 0.5
to 114 months. OS-time was defined as the period between
diagnosis and death. One-year PFS rate was 61%, 2-year PFS
rate was 30%, and after 5 years there have been 6% of the
patients without progression. Next to this 1-year OS rate was
79%, 2 yearOS ratewas 60%, and after 5 years it was 17%.After
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Table 4: Mean and median for overall survival (OS) and progression-free survival (PFS) in sPRR groups.
sPRR in
U/mL
𝑁 of
patients/%
Mean/medians for
OS in months
𝑁 of deaths
(censored)
Mean/medians for
PFS in months
𝑁 of progressions
(censored)
<6 56/28.4 39.9/31.6 38 (18) 29.7/12 48 (8)
6–25 89/45.2 49.6/41.5 57 (32) 34.8/14 77 (12)
>25 52/26.4 48.8/41.7 33 (19) 33.8/14 46 (6)
Overall 197/100 47.2/40 128 (69) 35.0/14 171 (26)
Table 5: Significance in equality log-rank tests (Mantel-Cox) of
sPRR with PFS and OS.
Log-rank (𝑝) Progression-free survival Overall survival
sPRR 0.651 0.395
sPRR (U/mL)
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Progression-free survival since surgery (months)
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6–25U/mL, censored
>25U/mL, censored
Figure 2: Progression-free survival curves for sPRR-level subgroups
(𝑝 = 0.651).
8 years 3 patients (1.5%) remained without progression and 6
patients (3%) have not died. Table 4 shows the distribution of
sPRR levels, mean and medians for OS/PFS, and numbers of
deaths/progressions.
Log-rank tests showedno significant relation ofOSor PFS
with sPRR levels (Table 5, Figures 2 and 3). Likewise there
was no correlation in pairwise comparison for the current
quartiles.
4. Discussion
This study has been designed to analyze a possible biomarker
in EOC patients, sPRR, regarding its correlation with several
clinical and pathological factors as well as progression-free
survival (PFS) and overall survival (OS).
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Figure 3: Overall survival curves for sPRR-level subgroups (𝑝 =
0.395).
There are no studies to date that have reported on the
clinical significance of sPRR and its relationship with survival
in ovarian cancer patients. But there might be coherence as
sPRR is an important factor in the renin-angiotensin system
(RAS), Wnt-cascade, and activation of mitogen-activated
protein kinase (MAPK) which all have been shown to be
upregulated in ovarian cancer.
4.1. Renin-Angiotensin System and Tumorigenesis. Linking
prorenin with PRR leads to transformation of angiotensino-
gen to angiotensin I which can start the RAS [14]. It is known
that RAS may be activated in human uterine endometrium,
ovary, and placenta both under physiological situations
and in malignancies [15–17]. An overview of Deshayes and
Nahmias showed that the RAS may be part of angiogen-
esis, cellular proliferation and apoptosis [18]. In ovarian
cancer patients upregulated angiotensin I receptor (AT1R)
is known to increase with the tumour invasiveness [13].
Pupilli et al. showed that the activation of AT1R stimulates
vascular endothelial growth factor (VEGF) and may lead to
angiogenesis in malignant diseases [19]. While angiotensin
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I seems to upregulate apoptosis and block angiogenesis
and proliferation, angiotensin II antagonizes theses effects
[20]. A disruptive factor on this balance of the RAS may
increase tumorigenesis through neovascularisation, growth,
and metastasis [21]. Lever et al. showed that ACE inhibitors
may protect against cancer, since the relative risk for female
cancers was 0.37 (0.12–0.87) compared with patients receiv-
ing other hypertensive drugs in a follow-up of 3 years [22].
Ino et al. investigated 67 ovarian cancer tissues immuno-
histochemically for AT1R, which was expressed in 85%
of the cases. Patients with positive tissues for AT1R had
significantly poorer outcome (𝑝 = 0.041) than those with
negative staining. AT1R expression also correlated with
increased VEGF [11]. In a study of Suganuma et al. AT1R
was immunohistochemically analyzed in 99 ovarian cancer
tissues. In this study VEGF was also significantly higher and
resulted in enhanced invasiveness when AT1R was expressed.
Using candesartan in transplanted mice reduced peritoneal
dissemination, decreased ascitic VEGF concentration, and
suppressed tumour angiogenesis [13].
Regarding angiotensin converting enzyme (ACE) Beyazit
et al. measured serum ACE levels in 41 patients and 19
controls. ACE levels were significantly upregulated in patients
with ovarian cancer. There was no correlation recognizable
for FIGO stages or pathologic subtypes [12].
4.2. Wnt/𝛽-Catenin Cascade and Progression-Free Survival in
Ovarian Cancer. Next to the transformation of angiotensino-
gen to angiotensin I, PRR is also capable of starting an intra-
cellular cascade beginning with the activation of promyelo-
cytic leukemia zinc finger (PLZF) protein and ending with
the production of Wnt target genes. The Wnt-cascade is a
key mediator of cell-cell communication and well known
to promote cell proliferation, differentiation, migration, and
tissue homeostasis [23].
Dai et al. showed evidence for upregulated genes of
the Wnt-cascade in ovarian cancer patients by differential
methylation hybridisation of 120 ovarian cancer tumours.
They identified two groups of gen loci deferring in their
progression-free survival (HR = 2.09; 95% CI (1.39, 3.15)) and
a significant correlation with pathologic factors in ovarian
cancer patients [24].
4.3. Increased Mitogen-Activated Protein Kinase (MAPK) in
Drug Resistant Ovarian Cancer. Binding of prorenin recep-
tor also starts the extracellular signal-regulated kinase 1/2
(Erk1/2) by activatingMAPK. Erk1/2 is known to increase cell
proliferation and upregulate profibrotic factors through the
transforming growth factor-𝛽1 (TGF-𝛽1) [25, 26].
A study of Xie et al. investigates the influence of MAPK
in 20 ovarian cancer tissues on Cisplatin sensitivity. The
immunohistochemical investigation of those tissues showed
significantly higher levels of MAPK in the drug resistant
tumours [27].
4.4. Limitations. As sPRR is part of the RAS, hypertension
might be a confounding factor. Nguyen et al. showed that
prorenin receptor levels in high blood pressure patients are
not deviating to those of healthy controls [28]. But ACE
inhibitors seem to have an impact on sPRR levels. Patients
that were treated with RAS blocking medicaments had ≈12%
higher sPRR levels than those with other therapies. As ACE
inhibitors are first choice in patients with cardiac or kidney
diseases and such diseases are known to correlate with
increased sPRR levels as well, the confounding factor is not
distinct yet.
It is known that a high amount of PRR is located in tissue
depending on its perfusion. This may implicate that serum
levels are not able to show increasing levels as good as tissue
analysis.
4.5. Further Investigations. Currently there are no studies
analyzing the influence of PRR on RAS, Wnt signalling,
or MAPK activation in ovarian cancer. As we analyzed the
soluble form in the serum of the patients further investiga-
tionsmay be, for example, immunohistochemicalmethods or
Western Blot to demonstrate PRR directly in ovarian cancer
tissue. Prospectively a potential predictive or prognostic
marker that can be analyzed after surgery to evaluate best
individual therapies is needed for ovarian cancer.
5. Conclusion
In this study no predictive, prognostic, or diagnostic values
for sPRR in the serum of ovarian cancer patients were shown.
There was no prognostic value in the survival analyses.
Further studies that analyze the receptor in the ovarian cancer
tissue are needed to make out which role PRR plays in the
oncogenesis of ovarian cancer.
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